E-commerce - Suning.com held the 618 e-commerce launch meeting, with offline stores nationwide participating in the promotion starting from May 13, 2023 [1] - The online promotion will also begin on May 13, with multiple promotional events scheduled throughout the 618 period [1] Legal Actions - Italian company Moltiply has filed a lawsuit against Google's parent company Alphabet, seeking €2.97 billion (approximately $3.34 billion) in damages for alleged abuse of market dominance [2] - The lawsuit claims that Google's actions hindered the development of Moltiply's subsidiary, 7Pixel, from 2010 to 2017 [2] Retail and Sales - During the "Young Product New Venue" merchant conference, it was reported that 6,120 brands on the Dewu platform have doubled their annual sales [4] - Dewu has introduced policies to reduce fees for over 30 categories, with a maximum reduction of 16%, and has invested over 1 billion yuan in marketing rebates [4] Automotive Industry - The three major U.S. automakers criticized the trade agreement between President Trump and the UK, which allows UK manufacturers to export 100,000 cars to the U.S. at a 10% tariff rate [5] - This quota is nearly equivalent to the total number of cars exported from the UK last year, raising concerns among U.S. manufacturers about competitive disadvantages [5] Technology and AI - Nvidia has open-sourced several code reasoning models, including 32B, 14B, and 7B parameters, based on Alibaba's Qwen models [6] - Quark, Alibaba's AI application, is set to launch "Deep Search Pro," which aims to assist users in solving complex tasks across various professional fields [10] Aviation - International Airlines Group (IAG) announced the purchase of 53 new long-haul aircraft from Boeing and Airbus, including 32 Boeing 787-10s and 21 Airbus A330-900neos [11] Financial Services - Zhongzheng Asset Management (Jiangsu) Co., Ltd. completed a 30 million yuan angel round of financing to accelerate the development of its intelligent investment advisory platform [8] - The funds will be used for platform development, team expansion, and market outreach [8] Pharmaceuticals - Fosun Pharma's subsidiary received FDA approval to conduct clinical trials for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia [9] - The cumulative R&D investment for LBP-ShC4 is approximately 17 million yuan as of April 2025 [9] Regulatory Developments - The People's Bank of China plans to deepen financial reform and enhance the monetary policy framework to support high-quality financial development [12][14] - The China Securities Regulatory Commission aims to strengthen the regulation of capital market activities to maintain a fair market order [13]

关于控股子公司获美国 FDA 药品临床试验批准的公告 证券代码：600196 股票简称：复星医药 编号：临 2025-085 上海复星医药（集团）股份有限公司 截至 2025 年 4 月，本集团现阶段针对 LBP-ShC4 的累计研发投入约为人民币 0.17 亿元（未经审计）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海 菌济健康科技有限公司（以下简称"菌济健康"）收到美国 FDA（即美国食品药品 监督管理局）关于同意 LBP-ShC4 开展临床试验的批准。菌济健康拟于条件具备后开 展 LBP-ShC4 的 I 期临床试验。 二、LBP-ShC4 的研究情况 LBP-ShC4 为本集团（即本公司及控股子公司/单位，下同）自主研发的活体生 物治疗产品，拟用于治疗雄激素脱发（AGA）。 截至本公告日期（2025 年 5 月 9 日），于全球范围内尚无用于治疗雄激素脱发 （AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。 三、风险提示 ...

Core Viewpoint - The first "Fosun Cup" AI+ Entrepreneurship and Innovation Competition has been launched, aiming to integrate cutting-edge technology with industry applications, leveraging Fosun's extensive resources and global industry scenarios [1][10]. Group 1: Competition Overview - The competition is supported by Fosun's global investment institution, Fosun Ruijing Capital, which will provide investments ranging from 5 million to 50 million yuan for the top three teams [3][11]. - Winning teams will also gain priority access to over 200 industry application scenarios, including AI applications in finance, healthcare, and intelligent manufacturing [3][11]. - The competition includes cash prizes of 100,000 yuan or equivalent resources for the top teams, along with direct recruitment opportunities for outstanding teams [4][11]. Group 2: Recruitment Tracks - The competition is recruiting AI pioneers across various tracks, including AI+Finance, AI+Healthcare, AI+Marketing, AI for Science (AI4S), and AI+Intelligent Agents [4][11]. - Each track focuses on specific applications of AI, such as financial data processing, drug development, and intelligent marketing solutions [4][11]. Group 3: Competition Schedule - The project recruitment phase runs until June 15, 2025, followed by a selection process to identify over 20 enterprises for the initial round [6][7]. - The initial round will take place from June 15 to June 30, 2025, where 20+ enterprises will compete for a spot in the finals [7]. - The final competition is scheduled for July 2025, where experts and executives will evaluate the projects through presentations [8]. Group 4: Fosun's Strategic Focus - Fosun emphasizes technology innovation as a core strategic pillar, building a global innovation system that integrates independent research, investment incubation, and ecological cooperation [10][11]. - The company has made significant investments in AI and robotics, with a focus on enhancing efficiency in drug development, medical imaging, and precision medicine [10][12]. - Fosun's subsidiaries, including Fosun Pharma and Fosun Wealth Holdings, are actively integrating AI into their operations to improve decision-making, operational efficiency, and market insights [12][14].

根据《公司章程》的规定，董事长为复星医药的法定代表人。本次调整后，复星医药的法定代表人将变 更为陈玉卿。 资料显示，陈玉卿，1975年12月出生，现任复星医药执行董事、董事长（均自2025年4月29日起任）， 并于复星医药若干控股子公司担任董事、管理层职务。陈玉卿于2010年1月加入复星医药，其间曾历任 公司人力资源部总经理、总裁助理、副总裁、高级副总裁、联席总裁、联席首席执行官等；于2020年8 月至2021年5月及2022年10月至今任控股子公司上海复星健康科技（集团）有限公司董事长；于2024年9 月至2025年4月任复星医药非执行董事。陈玉卿现任香港联交所上市公司复星国际有限公司（股票代 码：00656，以下简称"复星国际"）高级副总裁，并曾任复星国际副总裁。 加入复星医药前，陈玉卿于1997年7月至1999年7月任上海大学材料学院教师，于1999年7月至2005年3月 历任延锋伟世通汽车饰件系统有限公司（现更名为延锋汽车饰件系统有限公司）、延锋伟世通（北京） 汽车饰件系统有限公司、上海延锋江森座椅有限公司人力资源经理，于2005年6月至2006年4月任上海埃 力生（集团）有限公司人力资源部发展经理， ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年5月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 | RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 | RMB ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 回購股份的進展公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月6 日 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：600196 证券简称：复星 ...

证券代码：600196 证券简称：复星医药 公告编号：2025-084 关于回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） 截至 2025 年 4 月 30 日收市，回购进展如下： | | A 股回购方案 | H 股回购方案 | | --- | --- | --- | | 回购方案 | 2025/1/23 | 2025/1/23 | | 首次披露日 | | | | 回购方案 | 2025/1/22~2025/7/21 | 2025/1/22~2025/7/21 | | 实施期限 | | | | （含首尾两日） | | | | 预计回购金额 | 人民币30,000万元~60,000万元 | 不适用 | | | □减少注册资本 √用于员工持股计划或股权激励 | 包括但不限于注销或作为库存 股份等 | | 回购用途 | √用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | | （上述二者之一或二者皆有） | | | 累计已回购股数 | 7,310,552股A 股 ...

Summary of Key Points Core Viewpoint - On May 2, 37 Hong Kong-listed companies conducted share buybacks, totaling 23.26 million shares and an aggregate amount of HKD 179 million [1]. Group 1: Buyback Details - The company with the highest buyback amount on May 2 was Green Bamboo Bio-B, which repurchased 1.76 million shares for HKD 39.71 million, with a maximum price of HKD 23.00 and a minimum price of HKD 21.95 [1][2]. - China Hongqiao repurchased 2.79 million shares for HKD 39.39 million, with a maximum price of HKD 14.20 and a minimum price of HKD 14.02, bringing its total buyback amount for the year to HKD 20.74 billion [1][2]. - Swire Pacific A repurchased 0.33 million shares for HKD 22.59 million, with a maximum price of HKD 68.95 and a minimum price of HKD 66.95, totaling HKD 15.26 billion for the year [1][2]. Group 2: Notable Buybacks - AIA Group conducted multiple buybacks throughout the year, with a total buyback amount of HKD 7.69 billion, including a buyback of HKD 16.07 million on May 2 [2]. - The company with the highest number of shares repurchased on May 2 was Ying Group, which bought back 7 million shares [1][2]. - Other notable companies in terms of buyback volume included China Hongqiao and Four Seasons Pharmaceutical, with repurchases of 2.79 million shares and 2.68 million shares, respectively [1][2].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | | | --- | --- | --- | --- | | 表格類別： 呈交日期： | 股票 2025年5月2日 | 狀態： | 新提交 | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02196 | 說明 | | ...